Selected research
Industry Research
Personalized Radioimmunotherapy Industry Research Report 2026
Market perspective
The global Personalized Radioimmunotherapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Personalized Radioimmunotherapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Personalized Radioimmunotherapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Personalized Radioimmunotherapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Personalized Radioimmunotherapy include Novartis, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med, Nordic Nanovector and Mundipharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Personalized Radioimmunotherapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Personalized Radioimmunotherapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Personalized Radioimmunotherapy Market by Company
Novartis
Bayer
Y-mAbs Therapeutics
Telix Pharmaceuticals
RadioMedix
Philogen
Orano Med
Nordic Nanovector
Mundipharma
Lantheus
Gilead Sciences
Fusion Pharmaceuticals
Curium Pharmaceuticals
Curasight
Clarity Pharmaceuticals
China Isotope & Radiation
Aurobindo Pharma
Actinium Pharmaceuticals
Personalized Radioimmunotherapy Segment by Type
Beta-emitting
Targeted Alpha Therapy
Personalized Radioimmunotherapy Segment by Application
Solid Tumor
Non Hodgkin Lymphoma
Personalized Radioimmunotherapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Personalized Radioimmunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Personalized Radioimmunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Personalized Radioimmunotherapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Personalized Radioimmunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Beta-emitting
- Targeted Alpha Therapy
Applications
- Solid Tumor
- Non Hodgkin Lymphoma
Companies covered
- Novartis
- Bayer
- Y-mAbs Therapeutics
- Telix Pharmaceuticals
- RadioMedix
- Philogen
- Orano Med
- Nordic Nanovector
- Mundipharma
- Lantheus
- Gilead Sciences
- Fusion Pharmaceuticals
- Curium Pharmaceuticals
- Curasight
- Clarity Pharmaceuticals
- China Isotope & Radiation
- Aurobindo Pharma
- Actinium Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Personalized Radioimmunotherapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Beta-emitting
- 2.2.3 Targeted Alpha Therapy
- 2.3 Personalized Radioimmunotherapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Solid Tumor
- 2.3.3 Non Hodgkin Lymphoma
- 2.4 Assumptions and Limitations
3 Personalized Radioimmunotherapy Breakdown Data by Type
- 3.1 Global Personalized Radioimmunotherapy Historic Market Size by Type (2021-2026)
- 3.2 Global Personalized Radioimmunotherapy Forecasted Market Size by Type (2027-2032)
4 Personalized Radioimmunotherapy Breakdown Data by Application
- 4.1 Global Personalized Radioimmunotherapy Historic Market Size by Application (2021-2026)
- 4.2 Global Personalized Radioimmunotherapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Personalized Radioimmunotherapy Market Perspective (2021-2032)
- 5.2 Global Personalized Radioimmunotherapy Growth Trends by Region
- 5.2.1 Global Personalized Radioimmunotherapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Personalized Radioimmunotherapy Historic Market Size by Region (2021-2026)
- 5.2.3 Personalized Radioimmunotherapy Forecasted Market Size by Region (2027-2032)
- 5.3 Personalized Radioimmunotherapy Market Dynamics
- 5.3.1 Personalized Radioimmunotherapy Industry Trends
- 5.3.2 Personalized Radioimmunotherapy Market Drivers
- 5.3.3 Personalized Radioimmunotherapy Market Challenges
- 5.3.4 Personalized Radioimmunotherapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Personalized Radioimmunotherapy Players by Revenue
- 6.1.1 Global Top Personalized Radioimmunotherapy Players by Revenue (2021-2026)
- 6.1.2 Global Personalized Radioimmunotherapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Personalized Radioimmunotherapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Personalized Radioimmunotherapy Head Office and Area Served
- 6.4 Global Personalized Radioimmunotherapy Players, Product Type & Application
- 6.5 Global Personalized Radioimmunotherapy Manufacturers Established Date
- 6.6 Global Personalized Radioimmunotherapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Personalized Radioimmunotherapy Market Size (2021-2032)
- 7.2 North America Personalized Radioimmunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 7.4 North America Personalized Radioimmunotherapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Personalized Radioimmunotherapy Market Size (2021-2032)
- 8.2 Europe Personalized Radioimmunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 8.4 Europe Personalized Radioimmunotherapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Personalized Radioimmunotherapy Market Size (2021-2032)
- 9.2 Asia-Pacific Personalized Radioimmunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Personalized Radioimmunotherapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Personalized Radioimmunotherapy Market Size (2021-2032)
- 10.2 South America Personalized Radioimmunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 10.4 South America Personalized Radioimmunotherapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Personalized Radioimmunotherapy Market Size (2021-2032)
- 11.2 Middle East & Africa Personalized Radioimmunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Personalized Radioimmunotherapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis
- 12.1.1 Novartis Company Information
- 12.1.2 Novartis Business Overview
- 12.1.3 Novartis Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.1.4 Novartis Personalized Radioimmunotherapy Product Portfolio
- 12.1.5 Novartis Recent Developments
- 12.2 Bayer
- 12.2.1 Bayer Company Information
- 12.2.2 Bayer Business Overview
- 12.2.3 Bayer Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.2.4 Bayer Personalized Radioimmunotherapy Product Portfolio
- 12.2.5 Bayer Recent Developments
- 12.3 Y-mAbs Therapeutics
- 12.3.1 Y-mAbs Therapeutics Company Information
- 12.3.2 Y-mAbs Therapeutics Business Overview
- 12.3.3 Y-mAbs Therapeutics Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.3.4 Y-mAbs Therapeutics Personalized Radioimmunotherapy Product Portfolio
- 12.3.5 Y-mAbs Therapeutics Recent Developments
- 12.4 Telix Pharmaceuticals
- 12.4.1 Telix Pharmaceuticals Company Information
- 12.4.2 Telix Pharmaceuticals Business Overview
- 12.4.3 Telix Pharmaceuticals Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.4.4 Telix Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 12.4.5 Telix Pharmaceuticals Recent Developments
- 12.5 RadioMedix
- 12.5.1 RadioMedix Company Information
- 12.5.2 RadioMedix Business Overview
- 12.5.3 RadioMedix Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.5.4 RadioMedix Personalized Radioimmunotherapy Product Portfolio
- 12.5.5 RadioMedix Recent Developments
- 12.6 Philogen
- 12.6.1 Philogen Company Information
- 12.6.2 Philogen Business Overview
- 12.6.3 Philogen Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.6.4 Philogen Personalized Radioimmunotherapy Product Portfolio
- 12.6.5 Philogen Recent Developments
- 12.7 Orano Med
- 12.7.1 Orano Med Company Information
- 12.7.2 Orano Med Business Overview
- 12.7.3 Orano Med Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.7.4 Orano Med Personalized Radioimmunotherapy Product Portfolio
- 12.7.5 Orano Med Recent Developments
- 12.8 Nordic Nanovector
- 12.8.1 Nordic Nanovector Company Information
- 12.8.2 Nordic Nanovector Business Overview
- 12.8.3 Nordic Nanovector Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.8.4 Nordic Nanovector Personalized Radioimmunotherapy Product Portfolio
- 12.8.5 Nordic Nanovector Recent Developments
- 12.9 Mundipharma
- 12.9.1 Mundipharma Company Information
- 12.9.2 Mundipharma Business Overview
- 12.9.3 Mundipharma Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.9.4 Mundipharma Personalized Radioimmunotherapy Product Portfolio
- 12.9.5 Mundipharma Recent Developments
- 12.10 Lantheus
- 12.10.1 Lantheus Company Information
- 12.10.2 Lantheus Business Overview
- 12.10.3 Lantheus Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.10.4 Lantheus Personalized Radioimmunotherapy Product Portfolio
- 12.10.5 Lantheus Recent Developments
- 12.11 Gilead Sciences
- 12.11.1 Gilead Sciences Company Information
- 12.11.2 Gilead Sciences Business Overview
- 12.11.3 Gilead Sciences Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.11.4 Gilead Sciences Personalized Radioimmunotherapy Product Portfolio
- 12.11.5 Gilead Sciences Recent Developments
- 12.12 Fusion Pharmaceuticals
- 12.12.1 Fusion Pharmaceuticals Company Information
- 12.12.2 Fusion Pharmaceuticals Business Overview
- 12.12.3 Fusion Pharmaceuticals Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.12.4 Fusion Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 12.12.5 Fusion Pharmaceuticals Recent Developments
- 12.13 Curium Pharmaceuticals
- 12.13.1 Curium Pharmaceuticals Company Information
- 12.13.2 Curium Pharmaceuticals Business Overview
- 12.13.3 Curium Pharmaceuticals Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.13.4 Curium Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 12.13.5 Curium Pharmaceuticals Recent Developments
- 12.14 Curasight
- 12.14.1 Curasight Company Information
- 12.14.2 Curasight Business Overview
- 12.14.3 Curasight Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.14.4 Curasight Personalized Radioimmunotherapy Product Portfolio
- 12.14.5 Curasight Recent Developments
- 12.15 Clarity Pharmaceuticals
- 12.15.1 Clarity Pharmaceuticals Company Information
- 12.15.2 Clarity Pharmaceuticals Business Overview
- 12.15.3 Clarity Pharmaceuticals Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.15.4 Clarity Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 12.15.5 Clarity Pharmaceuticals Recent Developments
- 12.16 China Isotope & Radiation
- 12.16.1 China Isotope & Radiation Company Information
- 12.16.2 China Isotope & Radiation Business Overview
- 12.16.3 China Isotope & Radiation Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.16.4 China Isotope & Radiation Personalized Radioimmunotherapy Product Portfolio
- 12.16.5 China Isotope & Radiation Recent Developments
- 12.17 Aurobindo Pharma
- 12.17.1 Aurobindo Pharma Company Information
- 12.17.2 Aurobindo Pharma Business Overview
- 12.17.3 Aurobindo Pharma Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.17.4 Aurobindo Pharma Personalized Radioimmunotherapy Product Portfolio
- 12.17.5 Aurobindo Pharma Recent Developments
- 12.18 Actinium Pharmaceuticals
- 12.18.1 Actinium Pharmaceuticals Company Information
- 12.18.2 Actinium Pharmaceuticals Business Overview
- 12.18.3 Actinium Pharmaceuticals Revenue in Personalized Radioimmunotherapy Business (2021-2026)
- 12.18.4 Actinium Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 12.18.5 Actinium Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst